FIG. 5.

Point mutations in the predicted ZnFs abrogate AML/ETO function. (A) predicted structure of the ZnF domain in the ETO portion of AML/ETO. (B) C33A cells were transfected with 2 μg of MDR-1 CAT, 100 ng of CMV β-galactosidase expression plasmid, and 0.5 μg of the indicated AML/ETO (A/E) expression plasmids. CAT assays were quantitated and normalized to β-galactosidase activity. (C) Western blotting (as described in Materials and Methods) was performed on representative cell lysates used in panel B with the anti-AML N-terminal antibody.